No price history available.
Key financial summary
Financials in SEK| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | SEKm | 29,819 | 27,049 | 28,291 | 31,827 | 34,759 | 34,969 | N/A | N/A |
| Operating profit | SEKm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | SEKm | 3,239 | 2,970 | 2,491 | 2,412 | 1,638 | 2,258 | N/A | N/A |
| EPS reported | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | SEKm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | SEKm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | SEKm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in SEK| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Getinge AB, founded in 1904 and headquartered in Gothenburg, Sweden, is a prominent global supplier of medical technology solutions. The company's extensive portfolio is designed for critical healthcare environments, including operating rooms, intensive care units, and sterile processing facilities. Its operations are divided into three core segments: Acute Care Therapies, Life Science, and Surgical Workflows. Getinge offers a comprehensive array of specialized equipment and systems. This encompasses advanced solutions for sterile processing and containment, such as sterilizers, washers, isolators, and automated logistic systems. For the life sciences sector, they provide bioreactors, bioprocess control systems, and associated analytics tools. Within acute care and surgical settings, their offerings range from anesthesia machines, specialized monitoring systems, and various disposables, to instruments for cardiac surgery (like beating heart stabilizers), mechanical ventilation products, and extracorporeal life support (ECMO) solutions. Additionally, Getinge provides infrastructure for operating rooms, including lighting, tables, modular systems, and integrated management tools, alongside products for cleaning, disinfection, packaging, and comprehensive sterile supply management. Their product line further extends to diverse catheters (thoracic, endovascular), endoscopic vessel harvesting systems, patient flow and transport solutions, and specialized devices for vascular and cardiothoracic surgery. The company distributes its broad range of products globally through its proprietary sales companies, as well as via agents and distributors, serving markets across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Getinge AB, founded in 1904 and headquartered in Gothenburg, Sweden, is a prominent global supplier of medical technology solutions. The company's extensive portfolio is designed for critical healthcare environments, including operating rooms, intensive care units, and sterile processing facilities. Its operations are divided into three core segments: Acute Care Therapies, Life Science, and Surgical Workflows. Getinge offers a comprehensive array of specialized equipment and systems. This encompasses advanced solutions for sterile processing and containment, such as sterilizers, washers, isolators, and automated logistic systems. For the life sciences sector, they provide bioreactors, bioprocess control systems, and associated analytics tools. Within acute care and surgical settings, their offerings range from anesthesia machines, specialized monitoring systems, and various disposables, to instruments for cardiac surgery (like beating heart stabilizers), mechanical ventilation products, and extracorporeal life support (ECMO) solutions. Additionally, Getinge provides infrastructure for operating rooms, including lighting, tables, modular systems, and integrated management tools, alongside products for cleaning, disinfection, packaging, and comprehensive sterile supply management. Their product line further extends to diverse catheters (thoracic, endovascular), endoscopic vessel harvesting systems, patient flow and transport solutions, and specialized devices for vascular and cardiothoracic surgery. The company distributes its broad range of products globally through its proprietary sales companies, as well as via agents and distributors, serving markets across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region.
